Inhibition of Nitrofurantoin Reduction by Menthol Leads to Enhanced Antimicrobial Activity

Journal of Chemotherapy

Volumn 15, Issue 5, 2003, Pages 449-453

  Shahverdi, A R ^a   Fazeli, M R ^a   Rafii, F ^b   Kakavand, M ^a   Jamalifar, H ^a   Hamedi, J ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Enterobacteria; Menthol; Nitrofurantoin; Nitroreduction

Indexed keywords

MENTHOL; NITROFURANTOIN; NITROREDUCTASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CITROBACTER; DRUG INACTIVATION; DRUG POTENTIATION; ENTEROBACTER; ESCHERICHIA; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; REDUCTION; SALMONELLA;

EID: 0142186019     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.5.449     Document Type: Article

References (16)

1. Chamberlain RE. Chemotherapeutic properties of prominent nitrofurans. J Antimicrob Chemother 1976; 2: 325-336.
2. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 1994; 33: 23-30.
3. McOsker CC, Pollack JR, Andersen JA. Inhibition of bacterial protein synthesis by nitrofurantoin macrocrystals: an explanation for the continued efficacy of nitrofurantoin. R Soc Med Int Congr Symp Ser 1989; 154: 33-44.
4. Bryant C, DeLuca M. Purification and characterization of an oxygen-insensitive NAD(P)H nitroreductase from Enterobacter cloacae. J Biol Chem 1991; 266:4119-4125.
5. Heflich RH, Howard PC, Beland FA. 1-nitrosopyrene: an intermediate in the metabolic activation of 1-nitropyrene to a mutagen in Salmonella typhimurium. Mutat Res 1985; 149: 25-32.
6. Tatsumi K, Kitamura S, Narai N. Reductive metabolism of aromatic nitrocompounds including carcinogens by rabbit liver preparations. Cancer Res 1986; 46:1089-1093.
7. Whiteway J, Koziarz P, Veall J, et al. Oxygen-insensitive nitroreductases: analysis of the roles of nsfA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J Bacteriol 1998; 180:5529-5539.
8. Gillette JR, Kamm JJ, Sasame HA. Mechanism of P-nitrobenzoate reduction in liver: the possible role of cytochrome P-450 in liver microsomes. Mol Pharmacol 1968; 4: 541-548.
9. Kutcher WW, McCalla DR. Aerobic reduction of 5-nitro-furaldehyde semicarbazone by rat liver xanthine dehydrogenase. Biochem Pharmacol 1984; 33: 799-805.
10. Kato R, Takahashi A, Oshima T. Characteristics of nitro reduction of the carcinogenic agent, 4-nitroquinolone N-oxide. Biochem Pharmacol 1970; 19: 45-55.
11. Rafii F, Hansen EB. Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother 1998; 42: 1121-1126.
12. Shahverdi AR, Tavassoli F. First description on the nitrofurantoin potentiation activity. Daru, 2002; 10 (2): 90.
13. Shahverdi A R Bagheri M, Tavassoli, F. A novel In vitro nitrofurantoin resistance breaker activity of Mentha longifolia L. essential oil. J Med Plants 2002; 1(4): 35-40.
14. National committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 1990. NCCLS, Villanova, PA. Approved Standard, Document M2-A4.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 1990. NCCLS, Villanova, PA. Approved Standard, Document M7-A2.
16. Sisson G, Goodwin A, Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2116-2123.